Revolution Medicines (RVMD) News Today

Revolution Medicines, Inc. (NASDAQ: RVMD) received a significant regulatory development for its lead oncology drug, although shares decreased despite the favorable news. The catalyst strengthens the company’s potential to expand RASONQUE internationally and supports optimistic analyst views.

• Positive Sentiment: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for RASONQUE (daraxonrasib) as a once-daily treatment for adults with metastatic pancreatic cancer previously treated with at least one systemic therapy. Final authorization from the European Commission is still required. Revolution Medicines RASONQUE positive CHMP opinion
• Positive Sentiment: The recommendation was based on the Phase 3 RASolute 302 trial, which showed a 60% reduction in the risk of death versus chemotherapy, with statistically significant and clinically meaningful improvements across primary and key secondary endpoints. Benefits were reported regardless of tumor RAS mutation status, potentially broadening the drug’s addressable market. Revolution Medicines pancreatic cancer drug EU recommendation
• Positive Sentiment: Needham reaffirmed its Buy rating and set a $275 price target, while RBC raised its target to $260 and maintained an Outperform rating. These targets indicate analysts see substantial upside from the quoted share price. Analyst ratings and price targets
• Neutral Sentiment: Brokerages’ average target price is $234.76, reflecting continued confidence in RVMD’s pipeline and commercial prospects. However, the company remains loss-making, so valuation and execution expectations are high. Revolution Medicines average broker price target

The positive CHMP opinion is likely the main stock catalyst today. The decrease in shares despite the announcement may indicate that investors had already anticipated the decision or were taking profits after the stock’s strong prior performance; the authorization remains subject to the European Commission’s final decision.